Hims & Hers Copies Novo Nordisk's New Wegovy Pill

Why It Matters

A cheap compounded version threatens Novo's pricing power and raises safety and regulatory concerns, potentially reshaping the fast‑growing GLP‑1 weight‑loss market.

Key Takeaways

• Hims & Hers offers oral semaglutide for $49/month.
• Novo's oral Wegovy costs $149 per month.
• Novo vows legal action against compounded pill.
• 170,000 patients currently on Wegovy in US.
• Eli Lilly's oral GLP‑1 slated to launch soon.

Pulse Analysis

The GLP‑1 agonist class has become a cornerstone of obesity treatment, and Novo Nordisk’s oral formulation of semaglutide—marketed as Wegovy—was hailed as a breakthrough after its January launch. By offering a pill that bypasses injections, Novo aimed to capture a broader patient base and command premium pricing. Hims & Hers, leveraging the U.S. compounding exemption, introduced a knock‑off at a fraction of the cost, positioning itself as a budget‑friendly alternative for needle‑averse consumers.

Regulatory scrutiny now intensifies around Section 503A compounding practices, which permit pharmacies to produce small‑batch drugs when commercial supply is scarce. Novo argues that Wegovy is fully stocked, rendering the exemption inapplicable and labeling the compounded product as unsafe and untested. The company’s threat of legal action underscores a broader industry debate about intellectual‑property protection versus patient access, especially as the American Diabetes Association’s Obesity Association warns against non‑approved GLP‑1 formulations due to quality concerns.

The price disparity could pressure Novo to reconsider its pricing strategy, especially as Eli Lilly’s oral GLP‑1 candidate, orforglipron, nears market entry. If low‑cost compounded versions gain traction, insurers may favor them, eroding Novo’s revenue projections. Conversely, heightened regulatory enforcement could curb the spread of such alternatives, preserving the premium market for approved products. Stakeholders will watch how courts and the FDA balance innovation, safety, and affordability in this rapidly evolving therapeutic arena.